U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated initiation of Phase 3 program expected in the second quarte ...
Hello, everyone, and thank you for joining us to review CSPi's Fiscal 2025 First Quarter Financial Results, as well as recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback